PMID- 38426932
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 28
IP  - 6
DP  - 2024 Mar
TI  - Rhizoma Paridis saponins attenuate Gram-negative bacteria-induced inflammatory 
      acne by binding to KEAP1 and modulating Nrf2 and MAPK pathways.
PG  - e18146
LID - 10.1111/jcmm.18146 [doi]
LID - e18146
AB  - Acne vulgaris represents a chronic inflammatory condition, the pathogenesis of 
      which is closely associated with the altered skin microbiome. Recent studies have 
      implicated a profound role of Gram-negative bacteria in acne development, but 
      there is a lack of antiacne agents targeting these bacteria. Polyphyllins are 
      major components of Rhizoma Paridis with great anti-inflammatory potential. In 
      this study, we aimed to evaluate the antiacne effects and the underlying 
      mechanisms of PPH and a PPH-enriched Rhizoma Paridis extract (RPE) in treating 
      the Gram-negative bacteria-induced acne. PPH and RPE treatments significantly 
      suppressed the mRNA and protein expressions of interleukin (IL)-1beta and IL-6 in 
      lipopolysaccharide (LPS)-induced RAW 264.7 and HaCaT cells, along with the 
      intracellular reactive oxygen species (ROS) generation. Furthermore, PPH and RPE 
      inhibited the nuclear translocation of nuclear factor kappa-B (NF-kappaB) P65 in 
      LPS-induced RAW 264.7 cells. Based on molecular docking, PPH could bind to 
      kelch-like ECH-associated protein 1 (KEAP1) protein. PPH and RPE treatments could 
      activate nuclear factor erythroid 2-related factor 2 (NRF2) and upregulate haem 
      oxygenase-1 (HO-1). Moreover, RPE suppressed the mitogen-activated protein kinase 
      (MAPK) pathway. Therefore, PPH-enriched RPE showed anti-inflammatory and 
      antioxidative effects in vitro, which is promising for alternative antiacne 
      therapeutic.
CI  - (c) 2024 The Authors. Journal of Cellular and Molecular Medicine published by 
      Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
FAU - Yang, Yang
AU  - Yang Y
AD  - R&D Department, Yunnan Baiyao Group Health Products Co., Ltd, Kunming, Yunnan, 
      China.
AD  - R&D Department, East Asia Skin Health Research Center, Beijing, China.
AD  - R&D Department, Yunnan Baiyao Group Shanghai Science & Technology Co., Ltd, 
      Shanghai, China.
FAU - Wang, Chaofan
AU  - Wang C
AD  - State Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, 
      China Agricultural University, Beijing, China.
FAU - Wang, Juan
AU  - Wang J
AD  - R&D Department, East Asia Skin Health Research Center, Beijing, China.
AD  - Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, 
      Northwestern Polytechnical University, Xi'an, Shaanxi, China.
FAU - Yang, Lingli
AU  - Yang L
AD  - R&D Department, Yunnan Baiyao Group Health Products Co., Ltd, Kunming, Yunnan, 
      China.
AD  - R&D Department, East Asia Skin Health Research Center, Beijing, China.
AD  - R&D Department, Yunnan Baiyao Group Shanghai Science & Technology Co., Ltd, 
      Shanghai, China.
FAU - Lv, Zheng
AU  - Lv Z
AD  - State Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, 
      China Agricultural University, Beijing, China.
FAU - An, Quan
AU  - An Q
AD  - R&D Department, Yunnan Baiyao Group Health Products Co., Ltd, Kunming, Yunnan, 
      China.
AD  - R&D Department, East Asia Skin Health Research Center, Beijing, China.
AD  - R&D Department, Yunnan Baiyao Group Shanghai Science & Technology Co., Ltd, 
      Shanghai, China.
FAU - Wang, Yiming
AU  - Wang Y
AD  - R&D Department, East Asia Skin Health Research Center, Beijing, China.
FAU - Shao, Xue
AU  - Shao X
AD  - R&D Department, Yunnan Baiyao Group Health Products Co., Ltd, Kunming, Yunnan, 
      China.
AD  - R&D Department, East Asia Skin Health Research Center, Beijing, China.
AD  - R&D Department, Yunnan Baiyao Group Shanghai Science & Technology Co., Ltd, 
      Shanghai, China.
FAU - Wang, Fei
AU  - Wang F
AD  - R&D Department, Yunnan Baiyao Group Health Products Co., Ltd, Kunming, Yunnan, 
      China.
AD  - R&D Department, East Asia Skin Health Research Center, Beijing, China.
AD  - R&D Department, Yunnan Baiyao Group Shanghai Science & Technology Co., Ltd, 
      Shanghai, China.
FAU - Huo, Tong
AU  - Huo T
AD  - R&D Department, Yunnan Baiyao Group Health Products Co., Ltd, Kunming, Yunnan, 
      China.
AD  - R&D Department, East Asia Skin Health Research Center, Beijing, China.
AD  - R&D Department, Yunnan Baiyao Group Shanghai Science & Technology Co., Ltd, 
      Shanghai, China.
FAU - Liu, Jiali
AU  - Liu J
AD  - State Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, 
      China Agricultural University, Beijing, China.
FAU - Luo, Haoshu
AU  - Luo H
AD  - State Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, 
      China Agricultural University, Beijing, China.
FAU - Quan, Qianghua
AU  - Quan Q
AUID- ORCID: 0000-0002-4051-3359
AD  - R&D Department, Yunnan Baiyao Group Health Products Co., Ltd, Kunming, Yunnan, 
      China.
AD  - R&D Department, East Asia Skin Health Research Center, Beijing, China.
AD  - R&D Department, Yunnan Baiyao Group Shanghai Science & Technology Co., Ltd, 
      Shanghai, China.
LA  - eng
GR  - 2018ZF005/Yunnan Science and technology project/
PT  - Journal Article
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Kelch-Like ECH-Associated Protein 1)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Saponins)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (NF-kappa B)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - 0 (KEAP1 protein, human)
SB  - IM
MH  - Humans
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - NF-E2-Related Factor 2/genetics/metabolism
MH  - Kelch-Like ECH-Associated Protein 1/genetics/metabolism
MH  - Lipopolysaccharides/adverse effects
MH  - *Saponins/pharmacology/therapeutic use
MH  - Molecular Docking Simulation
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - NF-kappa B/metabolism
MH  - Gram-Negative Bacteria/metabolism
MH  - *Acne Vulgaris/drug therapy
MH  - Heme Oxygenase-1/genetics/metabolism
MH  - Inflammation/metabolism
PMC - PMC10906378
OTO - NOTNLM
OT  - Gram-negative bacteria
OT  - Rhizoma Paridis
OT  - acne vulgaris
OT  - anti-inflammation
OT  - kelch-like ECH-associated protein 1
OT  - mitogen-activated protein kinase
OT  - polyphyllin H
COIS- Yang Yang, Lingli Yang, Yiming Wang, Xue Shao, Fei Wang, Tong Huo, and Quan An 
      are employed by Yunnan Baiyao Group Health Products Co., Ltd. Juan Wangs was 
      employed by Yunnan Baiyao Group Health Products Co., Ltd.
EDAT- 2024/03/01 12:44
MHDA- 2024/03/04 06:47
PMCR- 2024/03/01
CRDT- 2024/03/01 10:23
PHST- 2023/09/30 00:00 [revised]
PHST- 2023/05/21 00:00 [received]
PHST- 2024/01/16 00:00 [accepted]
PHST- 2024/03/04 06:47 [medline]
PHST- 2024/03/01 12:44 [pubmed]
PHST- 2024/03/01 10:23 [entrez]
PHST- 2024/03/01 00:00 [pmc-release]
AID - JCMM18146 [pii]
AID - 10.1111/jcmm.18146 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2024 Mar;28(6):e18146. doi: 10.1111/jcmm.18146.